[go: up one dir, main page]

WO2005035525A3 - Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc) - Google Patents

Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc) Download PDF

Info

Publication number
WO2005035525A3
WO2005035525A3 PCT/US2004/029093 US2004029093W WO2005035525A3 WO 2005035525 A3 WO2005035525 A3 WO 2005035525A3 US 2004029093 W US2004029093 W US 2004029093W WO 2005035525 A3 WO2005035525 A3 WO 2005035525A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbonylpyrrolidine
amido
aryloxy
inhibitors
derivatives
Prior art date
Application number
PCT/US2004/029093
Other languages
English (en)
Other versions
WO2005035525A2 (fr
WO2005035525B1 (fr
Inventor
Robert B Perni
John J Court
Shawn D Britt
Janos Pitlik
Drie John H Van
Original Assignee
Vertex Pharma
Robert B Perni
John J Court
Shawn D Britt
Janos Pitlik
Drie John H Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04809688A priority Critical patent/EP1667998A2/fr
Priority to BRPI0414176-8A priority patent/BRPI0414176A/pt
Priority to JP2006525519A priority patent/JP4767852B2/ja
Priority to HK07102734.0A priority patent/HK1095594B/xx
Priority to MXPA06002476A priority patent/MXPA06002476A/es
Priority to NZ545158A priority patent/NZ545158A/en
Priority to AU2004279800A priority patent/AU2004279800B9/en
Priority to CA2536436A priority patent/CA2536436C/fr
Application filed by Vertex Pharma, Robert B Perni, John J Court, Shawn D Britt, Janos Pitlik, Drie John H Van filed Critical Vertex Pharma
Priority to CN2004800254182A priority patent/CN1845920B/zh
Publication of WO2005035525A2 publication Critical patent/WO2005035525A2/fr
Publication of WO2005035525A3 publication Critical patent/WO2005035525A3/fr
Priority to IL173627A priority patent/IL173627A0/en
Priority to NO20061426A priority patent/NO20061426L/no
Publication of WO2005035525B1 publication Critical patent/WO2005035525B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Ceramic Engineering (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)

Abstract

Cette invention concerne des composés inhibant l'activité des sérines protéases, plus particulièrement, l'activité de la protéase NS3-NS4A du virus de l'hépatite C (VHC). Lesdits composés agissent en intervenant dans le cycle de vie du virus de l'hépatite C, et sont utilisés comme agents antiviraux. Cette invention concerne également des composition comprenant ces composés, soit pour une utilisation ex vivo, soit pour une administration à un patient souffrant d'une infection à VHC. Cet invention concerne également des méthodes permettant de traiter une infection à VHC chez un patient, par administration d'une composition comprenant le composé décrit dans l'invention. En outre, on décrit des procédés permettant d'élaborer ces composés.
PCT/US2004/029093 2003-09-05 2004-09-07 Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc) WO2005035525A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2004279800A AU2004279800B9 (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2006525519A JP4767852B2 (ja) 2003-09-05 2004-09-07 セリンプロテアーゼ、特にｈｃｖｎｓ３‐ｎｓ４ａの阻害剤
HK07102734.0A HK1095594B (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MXPA06002476A MXPA06002476A (es) 2003-09-05 2004-09-07 Inhibidores de serina proteasas, particularmente proteasa ns3-ns4a de hcv.
NZ545158A NZ545158A (en) 2003-09-05 2004-09-07 2-Amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP04809688A EP1667998A2 (fr) 2003-09-05 2004-09-07 Dérivés de 2-amido-4-aryloxy-1-carbonylpyrrolidine en tant qu'inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
BRPI0414176-8A BRPI0414176A (pt) 2003-09-05 2004-09-07 inibidores de serina proteases, em particular hcv ns3-ns4a protease
CA2536436A CA2536436C (fr) 2003-09-05 2004-09-07 Derrives de la pyrrolidine 1-carbony 4-aryloxy 2-amido en tant qu'inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
CN2004800254182A CN1845920B (zh) 2003-09-05 2004-09-07 作为丝氨酸蛋白酶、特别是hcvns3-ns4a蛋白酶的抑制剂的2-氨基-4-芳氧基-1-羰基吡咯烷衍生物
IL173627A IL173627A0 (en) 2003-09-05 2006-02-09 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
NO20061426A NO20061426L (no) 2003-09-05 2006-03-29 Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50067003P 2003-09-05 2003-09-05
US60/500,670 2003-09-05

Publications (3)

Publication Number Publication Date
WO2005035525A2 WO2005035525A2 (fr) 2005-04-21
WO2005035525A3 true WO2005035525A3 (fr) 2005-10-20
WO2005035525B1 WO2005035525B1 (fr) 2006-04-06

Family

ID=34434831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029093 WO2005035525A2 (fr) 2003-09-05 2004-09-07 Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)

Country Status (19)

Country Link
US (4) US7378422B2 (fr)
EP (2) EP1667998A2 (fr)
JP (2) JP4767852B2 (fr)
KR (2) KR20120051751A (fr)
CN (2) CN1845920B (fr)
AR (1) AR045596A1 (fr)
AU (1) AU2004279800B9 (fr)
BR (1) BRPI0414176A (fr)
CA (1) CA2536436C (fr)
IL (1) IL173627A0 (fr)
MX (1) MXPA06002476A (fr)
MY (1) MY148123A (fr)
NO (1) NO20061426L (fr)
NZ (2) NZ545158A (fr)
PE (1) PE20050374A1 (fr)
RU (2) RU2440368C2 (fr)
TW (2) TWI359147B (fr)
UY (1) UY28500A1 (fr)
WO (1) WO2005035525A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409985A3 (fr) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de protéases, spécialement de la protéase ns3 du virus de l'hépatite c
DE60111509T2 (de) * 2000-04-03 2006-05-11 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
WO2004092161A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
UY28423A1 (es) 2003-07-18 2005-02-28 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2007532474A (ja) * 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ATE416789T1 (de) * 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
EP2311851A3 (fr) * 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
CN101212970B (zh) * 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
CN101242816B (zh) * 2005-06-30 2012-10-31 维罗贝股份有限公司 Hcv抑制剂
SG166791A1 (en) * 2005-07-25 2010-12-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
EP2256113A1 (fr) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérine protéases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
KR20080056295A (ko) 2005-10-11 2008-06-20 인터뮨, 인크. Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US8183413B2 (en) * 2006-01-20 2012-05-22 Kaneka Corporation Process for production of β-amino-α-hydroxy carboxamide derivative
US20090304631A1 (en) * 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
CA2643688A1 (fr) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
JP2009530382A (ja) * 2006-03-23 2009-08-27 シェーリング コーポレイション Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
WO2007137080A2 (fr) 2006-05-23 2007-11-29 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéases activatrices de canal
US7834190B2 (en) 2006-05-26 2010-11-16 Kaneka Corporation Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP1881001A1 (fr) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. Inhibiteurs de la sérine protéase HCV NS-3
CA2656816A1 (fr) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de serine proteases de l'hepatite c macrocycliques de type tetrazolyle
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
ES2423219T3 (es) 2006-11-15 2013-09-18 Vertex Pharmaceuticals (Canada) Incorporated Análogos de tiofeno para el tratamiento o prevención de infecciones por flavivirus
WO2008086053A1 (fr) * 2007-01-03 2008-07-17 Virobay, Inc. Inhibiteurs du vhc
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
DK2114924T3 (da) * 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
WO2008134398A1 (fr) * 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyle dipeptides de protéase de l'hépatite c
MX2009011867A (es) * 2007-05-03 2010-03-22 Array Biopharma Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
BRPI0811447A2 (pt) 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
WO2009032198A1 (fr) * 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comportant
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
JP2011051896A (ja) * 2007-12-21 2011-03-17 Kaneka Corp Ｎ−シクロプロピル−３−アミノ−２−ヒドロキシヘキサン酸アミド塩酸塩の製造方法
MX2010008109A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
KR20100118991A (ko) * 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
KR20120130173A (ko) 2009-12-24 2012-11-29 버텍스 파마슈티칼스 인코포레이티드 플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
WO2011119858A1 (fr) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues destinés au traitement ou à la prévention d'infections à flavivirus
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011119860A1 (fr) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues pour traiter ou prévenir les infections à flavivirus
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011156545A1 (fr) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Modèle dynamique viral pour une polythérapie contre le vhc
US20130157258A1 (en) 2010-06-15 2013-06-20 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
CA2803248A1 (fr) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Composes et methodes pour le traitement ou la prevention d'infections par flavivirus
WO2012006060A1 (fr) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Composés et méthodes de traitement ou de prévention d'infections à flavovirus
WO2012006070A1 (fr) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Composés et méthodes de traitement ou de prévention d'infections à flavivirus
CN103153978A (zh) 2010-08-17 2013-06-12 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒科病毒感染的化合物和方法
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
WO2013016499A1 (fr) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés du thiophène
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013072328A1 (fr) 2011-11-14 2013-05-23 Sanofi Utilisation de telaprevir et de composés associés pour le traitement de l'athérosclérose, d'une insuffisance cardiaque, de néphropathies, de maladies hépatiques ou de maladies inflammatoires
HK1205736A1 (en) 2012-02-16 2015-12-24 阿奇克斯制药公司 Linear peptide antibiotics
WO2014053533A1 (fr) 2012-10-05 2014-04-10 Sanofi Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
WO2014134251A1 (fr) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques
EP4445956A3 (fr) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
CN108699105A (zh) 2016-03-04 2018-10-23 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
HK1257565A1 (zh) 2016-03-04 2019-10-25 豪夫迈‧罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
EA201990069A1 (ru) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
EP3484859B1 (fr) 2016-07-18 2021-09-15 F. Hoffmann-La Roche AG Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1
EP3504197B1 (fr) * 2016-08-23 2021-11-17 F. Hoffmann-La Roche AG Nouveaux dérivés de trifluorométhylpropanamide utilisés comme inhibiteurs de htra1
CN109661389A (zh) 2016-08-23 2019-04-19 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
CA3053418A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composes et methodes de traitement de l'angiocholite biliaire primitive
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
WO2020117849A1 (fr) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Procédés d'analyse utilisant une courbe d'étalonnage dans un échantillon par surveillance de réaction d'isotopologues multiples
AU2023376006A1 (en) 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (fr) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO2001002424A2 (fr) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
WO2001040262A1 (fr) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Inhibiteurs d'alpha-cetoamides de la protease ns3 du virus de l'hepatite c
WO2001074768A2 (fr) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2002008256A2 (fr) * 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
WO2003087092A2 (fr) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2004092161A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA1341029C (fr) 1985-02-04 2000-06-20 Michael Kolb Inhibiteurs de la peptidase
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ATE71934T1 (de) 1985-06-07 1992-02-15 Ici America Inc Selektionierte difluorverbindungen.
US5231084A (en) 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
NZ223148A (en) 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
EP0356595A1 (fr) 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Inhibiteurs des peptidases
US5736520A (en) 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
EP0371179A1 (fr) 1988-10-28 1990-06-06 Merrell Dow Pharmaceuticals Inc. Analogues des substrats de peptidases
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
CA2098702A1 (fr) 1990-12-28 1992-06-29 James C. Powers Cetoamides, cetoacides et cetoesters de nature peptidique
JP2668003B2 (ja) 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
EP0604182B1 (fr) * 1992-12-22 2000-10-11 Eli Lilly And Company Inhibiteurs de la protéase du VIH
ES2317977T3 (es) 1992-12-29 2009-05-01 Abbott Laboratories Procedimientos e intermediarios para la preparacion de inhibidores de proteasa retrovirales.
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
AU1615895A (en) 1994-03-31 1995-10-12 Bristol-Myers Squibb Company Imidazole-containing inhibitors of farnesyl protein transferase
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU715558B2 (en) 1995-11-23 2000-02-03 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
JP2000502332A (ja) 1995-12-07 2000-02-29 ザ スクリップス リサーチ インスティテュート Ｈｉｖプロテアーゼ阻害剤
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
TR199802136T2 (xx) * 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
CA2254122A1 (fr) 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
ATE320432T1 (de) 1996-09-25 2006-04-15 Merck Sharp & Dohme Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
US6348608B1 (en) 1996-10-08 2002-02-19 Yian Shi Catalytic asymmetric epoxidation
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ES2281170T3 (es) * 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
US6117870A (en) 1998-11-12 2000-09-12 Fujirebio Kabushiki Kaisha Cyclic amide derivatives
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
BR0009167A (pt) 1999-03-19 2001-12-26 Vertex Pharma Inibidores de enzima impdh
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
EP1206449A1 (fr) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
EP1226237A2 (fr) 1999-08-31 2002-07-31 Basf Aktiengesellschaft Methode d'identification d'inhibiteurs de cdc25
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
US6624290B2 (en) 2000-02-08 2003-09-23 Schering Corporation Azapeptides useful in the treatment of Hepatitis C
EP1261611A2 (fr) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibiteurs de la prot ase ns3 du virus de l'h patite c
SK14192002A3 (sk) 2000-04-05 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
HUP0302957A2 (hu) * 2000-04-19 2003-12-29 Schering Corporation Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai
AU2001267886A1 (en) 2000-06-30 2002-01-14 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
CA2416603A1 (fr) 2000-07-20 2003-01-31 Merck & Co., Inc. Inhibition de la maturation et de la replication du virus de l'hepatite c
AU2001276988B2 (en) 2000-07-21 2007-01-25 Dendreon Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002008251A2 (fr) 2000-07-21 2002-01-31 Corvas International, Inc. Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6939692B2 (en) 2000-09-12 2005-09-06 Degussa Ag Nucleotide sequences coding for the pknB gene
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002198723A (ja) * 2000-11-02 2002-07-12 Ace Technol Co Ltd 広帯域指向性アンテナ
US6602718B1 (en) * 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
JP4848528B2 (ja) 2000-12-28 2011-12-28 株式会社Ｉｈｉ イオン質量分離方法及び装置、並びにイオンドーピング装置
NZ526703A (en) 2001-01-22 2004-12-24 Merck & Co Inc Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1356123A2 (fr) 2001-01-30 2003-10-29 Vertex Pharmaceuticals Incorporated Detection quantitative d'acides nucleiques
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
CA2441688C (fr) 2001-03-27 2014-01-21 Vertex Pharmaceuticals Incorporated Compositions et methodes de traitement de l'infection par le vhc
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
JP2005500322A (ja) 2001-07-03 2005-01-06 アルタナ　ファルマ　アクチエンゲゼルシャフト ３−フェニルイソセリンの製法
MXPA04000293A (es) * 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
WO2003035060A1 (fr) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
CA2465597A1 (fr) 2001-11-14 2003-06-12 Ben Zion Dolitzky Formes cristallines amorphes de losartan potassique et leur procede de preparation
CA2369711A1 (fr) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CN100475778C (zh) 2002-04-25 2009-04-08 小野药品工业株式会社 二酮肼衍生物化合物以及含有该化合物作为有效成分的药物
JP2006507235A (ja) 2002-08-01 2006-03-02 フアーマセツト・インコーポレイテツド フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CA2413705A1 (fr) 2002-12-06 2004-06-06 Raul Altman Utilisation de meloxicame avec un agent antiplaquettaire pour le traitement du syndrome coronarien aigu et de troubles connexes
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP2006517960A (ja) 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
WO2004101605A1 (fr) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
ATE486889T1 (de) 2003-03-05 2010-11-15 Boehringer Ingelheim Int Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ATE547412T1 (de) * 2003-04-11 2012-03-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
JP4447603B2 (ja) 2003-05-21 2010-04-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビター化合物
UY28423A1 (es) * 2003-07-18 2005-02-28 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
WO2005018330A1 (fr) 2003-08-18 2005-03-03 Pharmasset, Inc. Regime de dosage pour therapie contre flaviviridae
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20050120398A1 (en) 2003-09-12 2005-06-02 Vertex Pharmaceuticals Incorporated Animal model for HCV infection
US20050119189A1 (en) * 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
JP2007532474A (ja) * 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
ATE416789T1 (de) 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
JP4890254B2 (ja) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
ATE442355T1 (de) 2003-10-28 2009-09-15 Vertex Pharma Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1689857A1 (fr) 2003-12-01 2006-08-16 Vertex Pharmaceuticals Incorporated Compositions renfermant des cellules hepatiques foetales, et procedes utiles pour le traitement de l'infection par le vhc
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
EP2311851A3 (fr) * 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
CN103319464A (zh) 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
ES2328589T3 (es) 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
US7381827B2 (en) 2004-03-12 2008-06-03 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2005107745A1 (fr) 2004-05-06 2005-11-17 Schering Corporation Inhibiteur de l'hepatite c
EP1765283A4 (fr) * 2004-06-08 2012-11-28 Vertex Pharma Compositions pharmaceutiques
WO2006026352A1 (fr) 2004-08-27 2006-03-09 Schering Corporation Composes d'acylsulfonamide inhibiteurs de la serine protease ns3 du virus de l'hepatite c
TW201300108A (zh) * 2004-10-01 2013-01-01 Vertex Pharma Ｃ型肝炎病毒（ｈｃｖ）ｎｓ３-ｎｓ４ａ蛋白酶抑制劑
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
EP2256113A1 (fr) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérine protéases
BRPI0615029A2 (pt) * 2005-08-19 2009-06-16 Vertex Pharma processos e intermediários
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2643688A1 (fr) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-cristaux et compositions pharmaceutiques les comprenant
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US20070244334A1 (en) 2006-03-16 2007-10-18 Tanoury Gerald J Processes and intermediates for preparing steric compounds
EA018811B1 (ru) 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
CN101494979A (zh) 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
US7651520B2 (en) * 2006-05-30 2010-01-26 Ostial Solutions, Llc Means and method for the accurate placement of a stent at the ostium of an artery
AU2007254990A1 (en) 2006-05-31 2007-12-13 Vertex Pharmaceuticals Incorporated Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor
US7708294B2 (en) 2006-11-02 2010-05-04 Gm Global Technology Operations, Inc. Detachable dual-use platform apparatus and method
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US7959488B2 (en) * 2007-10-15 2011-06-14 Tania Alessandra Talamo Brassiere pad system

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (fr) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO2001002424A2 (fr) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
WO2001040262A1 (fr) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Inhibiteurs d'alpha-cetoamides de la protease ns3 du virus de l'hepatite c
WO2001074768A2 (fr) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2002008256A2 (fr) * 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
WO2003087092A2 (fr) * 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2004092161A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US8518874B2 (en) 2005-06-30 2013-08-27 Virobay, Inc. HCV inhibitors
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Also Published As

Publication number Publication date
TW200524912A (en) 2005-08-01
MY148123A (en) 2013-02-28
NZ545158A (en) 2009-11-27
US20080311079A1 (en) 2008-12-18
US7378422B2 (en) 2008-05-27
MXPA06002476A (es) 2006-06-20
EP1667998A2 (fr) 2006-06-14
HK1095594A1 (en) 2007-05-11
RU2440368C2 (ru) 2012-01-20
KR20120051751A (ko) 2012-05-22
TWI359147B (en) 2012-03-01
CN102408469A (zh) 2012-04-11
RU2006110934A (ru) 2007-10-10
AR045596A1 (es) 2005-11-02
AU2004279800B2 (en) 2011-06-30
CN1845920B (zh) 2011-11-09
US8217048B2 (en) 2012-07-10
RU2011137875A (ru) 2013-03-20
IL173627A0 (en) 2006-07-05
US7745444B2 (en) 2010-06-29
NO20061426L (no) 2006-03-29
WO2005035525A2 (fr) 2005-04-21
CA2536436A1 (fr) 2005-04-21
TW201127828A (en) 2011-08-16
AU2004279800A1 (en) 2005-04-21
JP2007504251A (ja) 2007-03-01
PE20050374A1 (es) 2005-05-30
NZ580205A (en) 2011-04-29
US20050137139A1 (en) 2005-06-23
JP2011157369A (ja) 2011-08-18
JP4767852B2 (ja) 2011-09-07
KR20060073610A (ko) 2006-06-28
US20110104115A1 (en) 2011-05-05
US20130116169A1 (en) 2013-05-09
CA2536436C (fr) 2013-04-09
BRPI0414176A (pt) 2006-10-31
EP2573083A1 (fr) 2013-03-27
CN1845920A (zh) 2006-10-11
UY28500A1 (es) 2005-04-29
AU2004279800B9 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
WO2005035525A3 (fr) Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
WO2005037860A3 (fr) Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
WO2005077969A3 (fr) Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
WO2003087092A3 (fr) Inhibiteurs de la serine protease, notamment de la protease ns3-ns4a du virus de l'hepatite c
WO2005007681A3 (fr) Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2006039488A3 (fr) Inhibition de la protease ns3-ns4a du vhc
WO2004093798A3 (fr) Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
WO2008106058A3 (fr) Inhibiteurs de sérine protéases
MXPA04000293A (es) Inhibidores de serina proteasa biciclica de puente.
WO2004113365A3 (fr) Inhibiteurs de la tripeptide hepatite c serine protease
EP1441720B8 (fr) Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
WO2004072243A3 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
WO2008002924A3 (fr) Inhibiteurs macrocycliques quinoxalinyliques des protéases à sérine du virus de l'hépatite c
WO2009053828A3 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
WO2007143694A3 (fr) Inhibiteurs oximyles macrocycliques de la protéase de l'hépatite c
WO2009076173A3 (fr) Composés à base de tripeptides fluorés inhibant la sérine protéase du vhc
WO2008022006A3 (fr) Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
WO2008021956A3 (fr) Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c
WO2001074768A3 (fr) Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2009076166A3 (fr) Inhibiteurs oximyles de la sérine protéase de vhc

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480025418.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT

WWE Wipo information: entry into national phase

Ref document number: 2004279800

Country of ref document: AU

Ref document number: 545158

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 173627

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200601271

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2536436

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004279800

Country of ref document: AU

Date of ref document: 20040907

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020067004325

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004279800

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002476

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006525519

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004809688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 772/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006110934

Country of ref document: RU

B Later publication of amended claims

Effective date: 20051026

WWP Wipo information: published in national office

Ref document number: 2004809688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067004325

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414176

Country of ref document: BR